Johnson & Johnson Submits NDA for Oral Icotrokinra in Plaque Psoriasis
Johnson & Johnson submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the interleukin (IL)-23 receptor for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis (PsO).